The Dog Aging Project has made national headlines in scientific and popular media for its innovative approach to understanding human aging by studying canine longevity.
Led by Matt Kaeberlein, Ph.D., Co-director, University of Washington Medicine Nathan Shock Center of Excellence in the Basic Biology of Aging, The Dog Aging Project aims to identify the genetic and environmental factors that underlie healthy aging to develop therapies--such as the use of the FDA-approved drug Rapamycin-- that extend healthy lifespan.
This webinar is geared for both the general public and research community. Dr. Kaeberlein will share updates on the Dog Aging Project’s key research, including a Longitudinal study, the Trial One Study with Rapamycin, and the Trial Two Study with Rapamycin. Details.
The webinar will include a 20-minute presentation followed by Q&A, facilitated by Steven N. Austad, Ph.D., Co-Principal Investigator of the Nathan Shock Centers Coordinating Center and Director of the Nathan Shock Center at the University of Alabama Birmingham.
The webinar is presented by the Nathan Shock Centers Coordinating Center and the University of Washington Nathan Shock Center.